Targeted Particles for Prostate Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as chemotherapy and radiation therapy, often result in severe side effects due to the systemic administration of cytotoxic agents that cannot distinguish between tumor cells and normal cells, leading to the destruction of healthy tissues and organs.
Innovation Solution
Development of targeted particles comprising a polymeric matrix with small molecule urea-based peptidase inhibitor targeting moieties that specifically bind to prostate-specific membrane antigen (PSMA), allowing for the selective delivery of therapeutic, diagnostic, or prophylactic agents directly to prostate cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic chemotherapy is administered to deliver therapeutic agents to tumor sites, then the therapeutic effect on tumors is improved, but severe side effects occur due to destruction of healthy cells
Solution Approach 1:
The patent applies local quality by designing particles with heterogeneous structure where different components serve specific functions: PSMA-targeting moieties for tumor-specific binding, therapeutic agents for cancer cell destruction, and biodegradable polymers for controlled release. This localized functional differentiation enables selective delivery to tumor sites while protecting healthy tissues from cytotoxic effects
Solution Approach 2:
The patent uses particles as intermediary carriers that mediate between the therapeutic agent and the target tumor cells. These particles bind specifically to PSMA on prostate cancer cells, transporting the therapeutic payload directly to the tumor site and releasing it through biodegradation, thereby eliminating the need for systemic circulation and reducing exposure of healthy cells to cytotoxic agents
2Reliability
If high doses of cytotoxic agents are administered to achieve therapeutically effective concentration at tumor site, then the therapeutic efficacy is improved, but side effects are worsened due to destruction of normal tissues
Solution Approach 1:
The patent segments the therapeutic system into discrete particles, each containing a controlled amount of therapeutic agent. This segmentation allows for precise dosing at the cellular level, delivering the required therapeutic concentration directly to tumor cells without requiring high systemic doses that would damage normal tissues
Solution Approach 2:
The patent changes the delivery parameter from systemic concentration to localized concentration at the tumor site. By using PSMA-targeted particles that accumulate specifically in prostate cancer tissues, the system achieves high local drug concentration where needed while maintaining low systemic exposure, thereby improving therapeutic efficacy without proportionally increasing side effects
3Object-affected harmful factors
If targeted particles are used to selectively deliver agents to prostate cancer cells, then side effects are minimized, but the complexity of the delivery system increases
Solution Approach 1:
The patent employs composite particle structures combining multiple materials with complementary properties: biodegradable polymers for controlled release, PSMA-targeting moieties for specific binding, and therapeutic agents for cancer cell destruction. This composite approach integrates multiple functions into a single delivery system, reducing overall system complexity compared to using separate targeted and therapeutic components
Solution Approach 2:
The patent merges the targeting function and therapeutic delivery function into a single integrated particle system. The PSMA-targeting moieties are conjugated directly to the therapeutic-containing particles, combining navigation and payload delivery into one unified mechanism, thereby simplifying the system architecture while achieving selective tumor targeting and reduced side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise delivery of agents to tumor sites, reducing the dose required, minimizing side effects, and potentially opening new avenues for personalized cancer therapy by targeting prostate cancer cells while sparing healthy tissues.
Implementation Method 1
small molecule urea-based peptidase inhibitor targeting moieties which specifically bind to prostate-specific membrane antigen (PSMA)
Implementation Method 2
The particles are internalized by prostate cancer cells through endocytosis
Implementation Method 3
The particles are internalized by prostate cancer cells through endocytosis, followed by degradation of the particles and release of the encapsulated agent
Data Source
Figure 1~2B
Figure 3~4
Figure 5A~6
AI summary
The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof.